gefitinib has been researched along with fibrinogen in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (fibrinogen) | Trials (fibrinogen) | Recent Studies (post-2010) (fibrinogen) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 34,477 | 1,707 | 7,083 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, M; Ge, CH; Ge, ZQ; Li, CY; Wang, XH; Yang, XM; Yu, M; Zhan, YQ; Zhang, JH | 1 |
| Cheng, H; Gao, W; Hao, J; Liu, J; Sun, C | 1 |
2 other study(ies) available for gefitinib and fibrinogen
| Article | Year |
|---|---|
Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway.
Topics: Cell Line; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibrinogen; Gefitinib; Humans; Neoplasm Proteins; Phosphorylation; Quinazolines; Recombinant Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transcriptional Activation | 2014 |
FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; Fibrinogen; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2020 |